Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC for SARS-CoV-2 ARDS
NCT04466098Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Provacel in COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), sponsored by Masonic Cancer Center. Started Jul 2020; status: completed.
02
Drugs
Provacel
03
Conditions
COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04466098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466098.